-
ChemoCentryx's Drug Gets U.S. FDA Nod For Treating Rare Autoimmune Disease Opens in a new window)
The drug, avacopan, which will be available under brand name Tavneos in the next few weeks, will have a wholesale price of between $150,000 and $200,000 per patient per year. -
Biosimilars Competition Helps Patients More Than Generic Competition Opens in a new window)
A notion in the policy community is that competition between biologics and their biosimilars does not save patients and taxpayers as much as well-functioning generic competition.Comments
-
‘Naively Ambitious’: How COVAX Failed on its Promise to Vaccinate the World Opens in a new window)
Conceived at the start of the pandemic, COVAX had lofty goals, promising fair and equitable access to Covid-19 vaccines for every country worldwide, and giving them for free to the poorest.Comments
-
Europe’s Largest Clinical Trial Sponsors Are Getting Better at Reporting Results Opens in a new window)
The 26 research institutions have run nearly 4,600 trials testing medicines and, so far, 641 sets of results have been made available.Comments
-
US FDA Unlikely To Issue Broad Biosimilar Guidance Saying Comparative Clinical Studies Unnecessary Opens in a new window)
OTBB head Sarah Yim says FDA internal thinking is not aligned on the idea and that a lot of convincing was necessary to drop the clinical study requirement for insulin biosimilars.Comments
-
Africans Welcome New Malaria Vaccine. But Is It a ‘Game Changer'? Opens in a new window)
When babies are born in western Kenya, where malaria is rife, many mothers are sent home from the hospital with one all-important baby gift: a bed net treated with insecticide.Comments
-
Rapid COVID-19 Tests Increasingly Scarce, Pricey as Demand from Employers Jumps Opens in a new window)
Nearly a dozen state governments said they are grappling with shortages of rapid tests, which provide on-the-spot results within minutes and are crucial for COVID-19 surveillance programs.Comments
-
Venezuelans Rely on the Kindness of Strangers to Pay for COVID-19 Treatment Opens in a new window)
The state of Venezuela's already overloaded and crumbling public health system, in which hospitals often lack access to even water, has pushed many to use costly private centers.Comments
-
WHO Prioritizes Access to Diabetes and Cancer Treatments in New Essential Medicines Lists Opens in a new window)
High prices and low availability still a major barrier for patients’ access to new and old medicines.Comments
-
Merck’s Covid-19 Drug Is a Boon for Wall Street and Main Street Opens in a new window)
Antiviral drugs that keep some coronavirus patients out of the hospital are badly needed, and investors know it.Comments
-
For the First Time, WHO Committee Recommends Action on High-Priced Essential Medicines Opens in a new window)
The suggestion was made in the latest report about treatments to be added to the WHO list of essential medicines.Comments
-
Drug-Pricing “Experts” And CBO Underestimate The Threat To Innovation Opens in a new window)
Polls show that 65% of voters would oppose the legislation to lower drug prices if it reduced the supply of new drugs.Comments
-
Virtual Event
The evolving landscape for biosimilars.Comments
-
Americans Spend More On Top Drugs Than Every Other Country Combined — And It’s Not Because They’re Buying More Opens in a new window)
For 17 of the 20 top-selling drugs in the world in 2020, pharmaceutical companies made more in revenue from U.S. sales than they did in every other country put together.Comments
-
Understanding the Aducanumab (Aduhelm) Approval in the US
This lecture will describe the US FDA approval of aducanumab (Aduhelm) for Alzheimer disease and the implications the approval has had across the US health care system.Comments
Comments